biostudies-literatureWislez MAstraZenecaIntergroupe Francophone de Cancérologie Thoraciquee005636https://www.ebi.ac.uk/biostudies/studies/S-EPMC9594538biostudies-literatureUnknown10(10)<h4>Background</h4>The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC).<h4>Methods</h4>In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalumab (750 mg every 2 weeks) and underwent surgery between 2 and 14 days after the last infusion. The primary endpoint was the complete surgical resection rate. Secondary endpoints included tumor response rate, major histopathological response (MPR: ≤10% remaining viable tumor cells), disease-free survival (DFS), overall survival (OS), durvalumab-related safety, and 90-day postoperative mortality (NCT03030131).<h4>Results</h4>Forty-six patients were eligible (median age 60.9 years); 67Journal for immunotherapy of cancerNeoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).PMC9594538ESR-15-11017IFCT-1601Damotte DWesteel VLavole AAssouad JMolinier OBrouchet LCarre OMilleron BMassiani MADubos-Arvis CMazieres JEgenod TCaliandro RMorin FZalcman GLanglais AAntoine MJeannin GWislez MLe Pimpec Barthes FfalseNeoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).<h4>Background</h4>The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC).<h4>Methods</h4>In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalumab (750 mg every 2 weeks) and underwent surgery between 2 and 14 days after the last infusion. The primary endpoint was the complete surgical resection rate. Secondary endpoints included tumor response rate, major histopathological response (MPR: ≤10% remaining viable tumor cells), disease-free survival (DFS), overall survival (OS), durvalumab-related safety, and 90-day postoperative mortality (NCT03030131).<h4>Results</h4>Forty-six patients were eligible (median age 60.9 years); 672022-01-01T00:00:00Z2022 Oct2026-07-14T17:17:35.417Z2026-06-21T03:12:40.247ZS-EPMC95945383627073310.1136/jitc-2022-005636